|
26.1.2007 |
EN |
Official Journal of the European Union |
C 18/4 |
Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006
(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))
(2007/C 18/03)
— Issuing, maintenance or modification of a national marketing authorisation
|
Date of the decision |
Name(s) of the medicinal product |
Holder(s) of the marketing authorization |
Member State concerned |
Date of notification |
|
13.12.2006 |
Glucomed |
See Annex I |
See Annex I |
14.12.2006 |
|
13.12.2006 |
Agopton |
See Annex II |
See Annex II |
14.12.2006 |
— Suspension of a national marketing authorization
|
Date of the decision |
Name(s) of the medicinal product |
Holder(s) of the marketing authorization |
Member State concerned |
Date of notification |
|
19.12.2006 |
Cetirizine Nordic Drugs |
See Annex III |
See Annex III |
21.12.2006 |
|
19.12.2006 |
Cetirizine Dermapharm |
See Annex IV |
See Annex IV |
21.12.2006 |
|
19.12.2006 |
Cetirizine Apex |
See Annex V |
See Annex V |
21.12.2006 |
(1) OJ L 311, 28.11.2001, p. 67.
(2) OJ L 311, 28.11.2001, p. 1.
ANNEX I
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES
|
Member State |
Marketing Authorisation Holder |
Applicant |
Invented name |
Strength |
Pharmaceutical Form |
Route of administration |
|||
|
Austria |
— |
|
Flexove |
625 mg |
Tablet |
Oral use |
|||
|
Belgium |
— |
|
Flexove |
625 mg |
Tablet |
Oral use |
|||
|
Cyprus |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Czech Republic |
— |
|
Flexove |
625 mg |
Tablet |
Oral use |
|||
|
Denmark |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Estonia |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Finland |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
France |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Germany |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Greece |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Hungary |
— |
|
Flexove |
625 mg |
Tablet |
Oral use |
|||
|
Ireland |
— |
|
Flexove |
625 mg |
Tablet |
Oral use |
|||
|
Italy |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Latvia |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Lithuania |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Luxemburg |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
The Netherlands |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Poland |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Portugal |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Slovakia |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Spain |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Sweden |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
United Kingdom |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Iceland |
— |
|
Glucomed |
625 mg |
Tablet |
Oral use |
|||
|
Norway |
— |
|
Flexove |
625 mg |
Tablet |
Oral use |
ANNEX II
LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
|
Member State |
Marketing Authorisation Holder |
Product name |
Strength |
Pharmaceutical form |
Route of administration |
||||||
|
Austria |
|
AGOPTON |
15 mg |
Capsule |
Oral use |
||||||
|
AGOPTON |
30 mg |
Capsule |
Oral use |
||||||||
|
AGOPTON Rapid |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
AGOPTON Rapid |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
Belgium |
|
DAKAR |
15mg |
Capsule |
Oral use |
||||||
|
DAKAR |
30 mg |
Capsule |
Oral use |
||||||||
|
NIBITOR |
30 mg |
Capsule |
Oral use |
||||||||
|
Denmark |
|
LANZO |
15 mg |
Capsule |
Oral use |
||||||
|
LANZO |
30 mg |
Capsule |
Oral use |
||||||||
|
Finland |
|
LANZO |
30 mg |
Capsule |
Oral use |
||||||
|
LANZO |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LANZO |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
France |
|
OGAST |
15 mg |
Capsule |
Oral use |
||||||
|
OGAST |
30 mg |
Capsule |
Oral use |
||||||||
|
LANZOR |
15 mg |
Capsule |
Oral use |
|||||||
|
LANZOR |
30 mg |
Capsule |
Oral use |
||||||||
|
Germany |
|
AGOPTON |
15 mg |
Capsule |
Oral use |
||||||
|
AGOPTON |
30 mg |
Capsule |
Oral use |
||||||||
|
LANZOR |
15 mg |
Capsule |
Oral use |
||||||||
|
LANZOR |
30 mg |
Capsule |
Oral use |
||||||||
|
Greece |
|
LAPRAZOL |
15 mg |
Capsule |
Oral use |
||||||
|
LAPRAZOL |
30 mg |
Capsule |
Oral use |
||||||||
|
LAPRAZOL FasTab |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LAPRAZOL FasTab |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
Hungary |
|
LANSONE |
30 mg |
Capsule |
Oral use |
||||||
|
Ireland |
|
ZOTON |
15 mg |
Capsule |
Oral use |
||||||
|
ZOTON |
30 mg |
Capsule |
Oral use |
||||||||
|
ZOTON FasTab |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
ZOTON FasTab |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
ZOTON |
30mg |
Gastro-resistant granules for oral suspension |
Oral use |
|||||||
|
Italy |
|
LANSOX |
15 mg |
Capsule |
Oral use |
||||||
|
LANSOX |
30 mg |
Capsule |
Oral use |
||||||||
|
LANGAST |
15 mg |
Capsule |
Oral use |
||||||||
|
LANGAST |
30 mg |
Capsule |
Oral use |
||||||||
|
LANSOX |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LANSOX |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LIMPIDEX |
15 mg |
Capsule |
Oral use |
|||||||
|
LIMPIDEX |
30 mg |
Capsule |
Oral use |
||||||||
|
LIMPIDEX |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LIMPIDEX |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
ZOTON |
15 mg |
Capsule |
Oral use |
|||||||
|
ZOTON |
30 mg |
Capsule |
Oral use |
||||||||
|
ZOTON |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
ZOTON |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
Luxembourg |
|
DAKAR |
15 mg |
Capsule |
Oral use |
||||||
|
DAKAR |
30 mg |
Capsule |
Oral use |
||||||||
|
Netherlands |
|
PREZAL |
15 mg |
Capsule |
Oral use |
||||||
|
PREZAL |
30 mg |
Capsule |
Oral use |
||||||||
|
Portugal |
|
OGASTO |
15 mg |
Capsule |
Oral use |
||||||
|
OGASTO |
30 mg |
Capsule |
Oral use |
||||||||
|
OGASTO |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
OGASTO |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
Spain |
|
OPIREN |
15 mg |
Capsule |
Oral use |
||||||
|
OPIREN |
30 mg |
Capsule |
Oral use |
||||||||
|
BAMALITE |
15 mg |
Capsule |
Oral use |
||||||||
|
BAMALITE |
30 mg |
Capsule |
Oral use |
||||||||
|
OPIREN Flas |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
OPIREN Flas |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
BAMALITE Flas |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
BAMALITE Flas |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
Sweden |
|
LANZO |
15 mg |
Capsule |
Oral use |
||||||
|
LANZO |
30 mg |
Capsule |
Oral use |
||||||||
|
LANZO |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LANZO |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
United Kingdom |
|
ZOTON |
15 mg |
Capsule |
Oral use |
||||||
|
ZOTON |
30 mg |
Capsule |
Oral use |
||||||||
|
ZOTON |
30 mg |
Gastro-resistant granules for oral suspension |
Oral use |
||||||||
|
ZOTON FasTab |
15 mg |
Oro-dispersible Tablet |
Oral use |
||||||||
|
ZOTON FasTab |
30 mg |
Oro-dispersible Tablet |
Oral use |
||||||||
|
Iceland |
|
LANZO |
15 mg |
Capsule |
Oral use |
||||||
|
LANZO |
30 mg |
Capsule |
Oral use |
||||||||
|
ZOTON |
15 mg |
Capsule |
Oral use |
||||||||
|
ZOTON |
30 mg |
Capsule |
Oral use |
||||||||
|
LANZO |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LANZO |
30 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
Norway |
|
LANZO |
15 mg |
Capsule |
Oral use |
||||||
|
LANZO |
30 mg |
Capsule |
Oral use |
||||||||
|
LANZO |
15 mg |
Oro-dispersible tablet |
Oral use |
||||||||
|
LANZO |
30 mg |
Oro-dispersible tablet |
Oral use |
ANNEX III
LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
CETIRIZINE DIHYDROCHLORIDE NORDIC DRUGS 10 mg AND ASSOCIATED NAMES
|
Member State |
Marketing Authorisation Holder |
Product Name |
Strength |
Pharmaceutical Form |
Route of administration |
||||
|
Denmark |
|
Gardex |
10 mg |
Film coated tablet |
Oral |
||||
|
Finland |
|
Gardex 10 mg tabletti, kalvopäällysteinen |
10 mg |
Film coated tablet |
Oral |
||||
|
Netherlands |
|
Cetirizine dihydrochloride Nordic Drugs 10 mg |
10 mg |
Film coated tablet |
Oral |
||||
|
Norway |
|
Acura |
10 mg |
Film coated tablet |
Oral |
||||
|
Sweden |
|
Acura |
10 mg |
Film coated tablet |
Oral |
ANNEX IV
LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
CETIRIZINE DIHYDROCHLORIDE DERMAPHARM 10 mg AND ASSOCIATED NAMES
|
Member State |
Marketing Authorisation Holder |
Product Name |
Strength |
Pharmaceutical Form |
Route of administration |
|||
|
Austria |
|
Cetiderm 10 mg Filmtabletten |
10 mg |
Film coated tablet |
Oral |
|||
|
Belgium |
|
Cetirizine dihydrochloride Dermapharm 10 mg filmomhulde tabletten |
10 mg |
Film coated tablet |
Oral |
|||
|
Germany |
|
Cetiderm 10 mg Filmtabletten |
10 mg |
Film coated tablet |
Oral |
|||
|
Netherlands |
|
Cetirizine dihydrochloride Dermapharm 10 mg tabletten |
10 mg |
Film coated tablet |
Oral |
ANNEX V
LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
CETIRIZINE DIHYDROCHLORIDE APEX 10 mg AND ASSOCIATED NAMES
|
Member State |
Marketing Authorisation Holder |
Product Name |
Strength |
Pharmaceutical Form |
Route of administration |
||||||
|
Belgium |
|
Doccetiri |
10 mg |
Film coated tablet |
Oral |
||||||
|
Luxembourg |
|
Doccetiri-10 |
10 mg |
Film coated tablet |
Oral |
||||||
|
Netherlands |
|
Cetirizine dihydrochloride-APEX 10 mg |
10 mg |
Film coated tablet |
Oral |